Összefoglaló. Bevezetés: A krónikus lymphoid leukémia kezelésében jelentős előrelépést eredményezett az ibrutinibterápia bevezetése. A gyógyszer első vonalbeli és többed vonalbeli kezelése is magas remissziós arányt eredményezett, bár a terápia korai bevezetése és a kedvező genetikai eltérések esetén az eredmények jobbak. A progressziómentes túlélést befolyásoló egyéb tényezőkről azonban még kevés adat áll rendelkezésre. Célkitűzés: Krónikus lymphoid leukémiás betegek ibrutinibkezelése során a teljes hematológiai remisszió elérését és a progressziómentes túlélés időtartamát befolyásoló tényezők vizsgálata. Betegek és módszer: 47 krónikus lymphoid leukémiás beteg (életkor: 39–84 év, férfi 27, nő 20, követési idő 5–58 hónap, medián 15 hónap) klinikai és laboratóriumi adatainak retrospektív elemzése. Eredmények: A teljes hematológiai remisszió elérése független volt a betegek nemétől, életkorától, a betegség stádiumától, az immunglobulin gén nehézlánc-variábilis régió státuszától, a genetikai aberrációktól, az abszolút neutrophilszámtól, az abszolút monocytaszámtól és a vörösvértestnagyság-eloszlási görbe szélességétől. A progressziómentes túlélést a komplett remisszió elérése (p = 0,00073) és a magasabb abszolút neutrophilszám (<4 G/l vs. ≥4 G/l, p = 0,022) befolyásolta szignifikánsan, a vörösvértestnagyság-eloszlási görbe szélességértékével való összefüggés pedig statisztikailag határértéken volt (p = 0,065). A Cox-féle regressziós elemzésbe bevont változók közül csak a teljes hematológiai remisszió elérése mutatott szignifikáns hatást a progressziómentes túlélésre (p = 0,0147). Következtetések: A teljes hematológiai remisszió elérése az egyéb vizsgált tényezőktől független, szignifikáns hatással bír a betegek progressziómentes túlélésére. Az abszolút neutrophilszám és a vörösvértestnagyság-eloszlási görbe szélessége szintén hasznos kiegészítő prognosztikus marker lehet. Az elemzett esetek száma még alacsony a komolyabb következtetések levonására, azonban így is elmondható, hogy az eredmények egy része már a szakirodalom korábbi eredményeit tükrözi.
Summary. Introduction: The introduction of ibrutinib therapy has led to significant advances in the treatment of chronic lymphocytic leukemia. Both first-line and multiple-lines treatments of the drug resulted in high remission rates, although results were better with early initiation of therapy and favorable genetic abnormalities. However, little data are available on other factors influencing progression-free survival. Objective: To investigate factors influencing the achievement of complete hematological remission and progression-free survival with ibrutinib treatment in patients with chronic lymphocytic leukemia. Patients and metods: Retrospective analysis of clinical and laboratory data from 47 chronic lymphoid leukemia patients (age: 39–84 years, male 27, female 20, follow-up 5–58 months, median 15 months). Results: Achieving complete hematologic remission was independent of patient gender, age, disease stage, immunoglobulin heavy chain variable region status, genetic aberrations, absolute neutrophil count, absolute monocyte count, and red blood cell distribution width. Progression-free survival was significantly affected by complete remission (p = 0.00073), and higher absolute neutrophil counts (<4 G/l vs. ≥ 4 G/l, p = 0.022), the red blood cell distribution width was statistically less significant (p = 0.065). Of the variables included in the Cox regression analysis, only the achievement of complete hematologic remission had a significant effect on progression-free survival (p = 0.0147). Conclusions: Achieving complete hematologic remission, independent of the other factors studied, has a significant effect on patients’ progression-free survival. Absolute neutrophil count and red blood cell distribution width can also be a useful additional prognostic marker. The number of analyzed cases is still low to draw more serious conclusions, but it can still be said that some of the results already reflect previous results in the literature.
O’Brien S, Jones JA, Coutre SE, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol 2016; 17: 1409–1418.
O’Brien S, Furman RR, Coutre S, et al. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood 2018; 131: 1910–1919.
Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 2018; 379: 2517–2528.
O’Brien SM, Jaglowski S, Byrd JC, et al. Prognostic factors for complete response to ibrutinib patients with chronic lymphocytic leukemia: A pooled analysis of 2 clinical trials. JAMA Oncol 2018; 4: 712–716.
Sigmund A, Huang Y, Ruppert AS, et al. Depth of response and progression free survival in CLL patients on ibrutinib [abstract]. J Clin Oncol 2018; 36(Suppl 15). Abstract 7514.
Byrd JC, Hillmen P, O’Brien S, et al. Long-term follow-up of the RESONATE phase 3 trial ibrutinib vs. ofatumumab. Blood 2019; 133: 2031–2042.
Hallek M, Cheson BD, Catovsky D, et al. International workshop on chronic lymphocytic leukemia. Guidlines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International workshop on chronic lymphocytic leukemia updating the National Cancer Institute – Working Group 1996 Guidelines. Blood 2008; 111: 5446–5456.
Strati P, Schlette EJ, Solis Soto LM, et al. Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors. Blood 2020; 135: 510–513.
Mazumdar R, Evans P, Culpin R, et al. The automated monocyte count is independently predictive of overall survival from diagnosis in chronic lymphocytic leukaemia and of survival following first-line chemotherapy. Leuk Res 2013; 6: 614–618.
Herishanu J, Kay S, Sarid N, et al. Absolute monocyte count trichotomizes chronic lymphocytic leukemia into high risk patients with immune dysregulation, disease progression and poor survival. Leuk Res 2013; 37: 1222–1228.
Szerafin L, Jakó J, Riskó F. Prognostic value of absolute monocyte count in chronic lymphocytic leukaemia. [Az abszolút monocytaszám prognosztikus értéke krónikus lymphoid leukaemiában.] Orv Hetil 2015; 156: 592–597. [Hungarian]
Friedman DR, Sibley AB, Owzar K, et al. Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: a multi-institutional study. Am J Hematol 2016; 91: 687–691.
Kridel R, Steidl C, Gascoyne RD. Tumor-associated macrophages in diffuse large B-cell lymphoma. Haematologica 2015; 100: 143–145.
Riihijarvl S, Fiskvik I, Taskinen M, et al. Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial. Haematologica 2015; 100: 238–245.
Marcheselli R, Franchesetto A, Sacchi S, et al. The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis. Leuk Lymphoma 2019; 60: 1958–1964.
Burger JA, Gribben JG. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin Cancer Biol 2014; 24: 71–81.
Mantovani A, Marchesi F, Malesci A, et al. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 2017; 147: 399–416.
Asmaa MZ, Sawsan MM, Ahmad FT, et al. Monocytic myeloid-derived suppressor cells in chronic lymphocytic leukemia patients: A single center experience. Leuk Lymphoma 2020; 61: 1645–1652.
Fiorcari S, Maffei R, Auditro V, et al. Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia. Oncotarget 2016; 7: 65968–65981.
Levy I, Vadasz Z, Polliack A, et al. The frequency and prognostic value of neutrophilia in chronic lymphocytic leukemia. Anticancer Res 2018; 38: 4731–4734.
Patel KV, Ferrucci L, Ershler WB, et al. Red blood cell distribution width and the risk of death in middle-aged and older adults. Arch Intern Med 2009; 169: 515–523.
Patel HH, Patel HR, Higgins JM. Modulation of red blood cell population dynamics is a fundamental homeostatic response to disease. Am J Hematol 2015; 90: 422–428.
Lam AP, Gundabolu K, Sridharan A, et al. Multiplicative interaction between mean corpuscular volume and red cell distribution width in predicting mortality of elderly patiens with and without anemia. Am J Hematol 2013; 88: e245–e248.
Horne BD, Anderson JL, Muhlestein JB, et al. Complete blood risk score its components, including RDW, are associated with mortality in the JUPITER trial. Eur J Prev Cardiol 2014; 22: 519–526.
Goyal H, Lippi G, Gjymishka A, et al. Prognostic significance of red blood cell distribution width in gastrointestinal disorders. World J Gastroenterol 2017; 23: 4879–4891.
Solak Y, Yilmaz MI, Saglam M, et al. Red cell distribution width is independently related to endothelial dysfunction in patients with chronic kidney disease. Am J Med Sci 2014; 347: 118–124.
Koma Y, Onishi A, Matsuoka H, et al. Increased red blood cell distribution width associates with cancer stage and prognosis in patients with lung cancer. Plos One 2013; 8: e80240.
Lee H, Kong S-Y, Sohn Y-J, et al. Elevated red blood cell distribution width as a simple prognostic factor in patients with symptomatic multiple myeloma. BioMed Res Int 2014; 2014: 145619.
Beltran BE, Paredes S, Castro D, et al. High red cell distribution width is an adverse predictive and prognostic factor in patients with diffuse large B-Cell lymphoma treated with chemoimmunotherapy. Clin Lymphoma Myeloma Leuk 2019; 19: e551–e557.
Baba Y, Saito B, Shimada S, et al. Association of red cell distribution width with clinical outcomes in myelodysplastic syndrome. Leuk Res 2018; 67: 56–59.
Shi Z, Li B, Huang H, et al. Prognostic impact of red blood cell distribution width in myelodysplastic syndromes. Br J Haematol 2019; 186: 327–384.
Podhorecka M, Halicka D, Szymczyk A, et al. Assessment of red blood cell distribution with as a prognostic marker in chronic lymphocytic leukemia. Oncotarget 2016; 7: 32846–32853.
Gordon MJ, Sitlinger A, Salous T, et al. A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study. Leuk Res 2020; 89: 106–302.